CTOs on the Move

Kolltan

www.kolltan.com

 
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kolltan.com
  • 300 George St Ste 530
    New Haven, CT USA 06511
  • Phone: 203.773.3000

Executives

Name Title Contact Details

Similar Companies

Westwood Health Care Ctr

Westwood Health Care Ctr is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

nuMedica

nuMedica is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

York Hospital

York Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in York, ME. To find more information about York Hospital, please visit www.yorkhospital.com

Palisades Medical Center

Palisades Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Palisades Medical Center is based in North Bergen, NJ. You can find more information on Palisades Medical Center at www.palisadesmedical.org